Evaluating Systemic Therapy in Localized Renal Cell Carcinoma

This chapter explores the changing landscape of systemic therapy following curative nephrectomy in localized renal cell carcinoma, focusing on immune therapies and VEGF-targeted strategies. It discusses the mixed results in overall survival improvements and highlights pembrolizumab's potential for high-risk patients, while also addressing challenges in treating non-clear cell RCC.